HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of de novo DNA methyltransferases and methyl CpG-binding proteins in gene silencing in a rat hepatoma.

Abstract
The expression of metallothionein-I (MT-I), a known antioxidant, was suppressed in a transplanted rat hepatoma because of promoter methylation and was induced by heavy metals only after demethylation by 5-azacytidine (5-AzaC). Treatment of the tumor-bearing rats with 5-AzaC resulted in significant regression of the hepatoma. When the inhibitor-treated tumor was allowed to grow in a new host, MT-I promoter was remethylated, which suggested de novo methylation. The activities of both de novo (3-fold) and maintenance DNA methyltransferases (DNMT) (5-fold) were higher in the hepatoma than in the host liver. The mRNA levels of the de novo methyltransferases DNMT3a and DNMT3b were 3- and 6-fold higher, respectively, in the tumor implicating transcriptional up-regulation of these two genes in this tissue. Immunohistochemical analysis showed exclusive localization of DNMT3a in the nuclei of both the liver and hepatoma, whereas DNMT3b was detected in the nuclei as well as the cytoplasm. Immunoblot assay showed that the levels of DNMT1, DNMT3a, and DNMT3b proteins in the hepatoma were 5-, 10-, and 4-fold higher, respectively, than in the liver. The mRNA level of the major methyl CpG-binding protein (MeCP2) was 8-fold higher in the tumor compared with the liver. Immunohistochemical studies showed that MeCP2 is localized exclusively in the nuclei of both tissues. A chromatin immunoprecipitation assay demonstrated that MeCP2 was associated with the MT-I promoter in the hepatoma implicating its involvement in repressing the methylated promoter. Analysis of the DNA isolated from the liver and hepatoma by RLGS-M (restriction landmark genomic scanning with methylation-sensitive enzyme) (NotI) showed that many genes in addition to MT-I were methylated in the hepatoma. These data demonstrate suppression of the MT-I gene and probably other genes in a solid tumor by promoter methylation and have provided potential molecular mechanisms for the altered methylation profile of the genes in this tumor.
AuthorsSarmila Majumder, Kalpana Ghoshal, Jharna Datta, Shoumei Bai, Xiaocheng Dong, Ning Quan, Christoph Plass, Samson T Jacob
JournalThe Journal of biological chemistry (J Biol Chem) Vol. 277 Issue 18 Pg. 16048-58 (May 03 2002) ISSN: 0021-9258 [Print] United States
PMID11844796 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Retracted Publication)
Chemical References
  • Carrier Proteins
  • DNA-Binding Proteins
  • Dinucleoside Phosphates
  • cytidylyl-3'-5'-guanosine
  • Metallothionein
  • DNA-Cytosine Methylases
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases
  • Dnmt1 protein, rat
  • Azacitidine
Topics
  • Animals
  • Azacitidine (pharmacology)
  • Base Sequence
  • Carrier Proteins (metabolism)
  • Cell Nucleus (enzymology)
  • DNA (Cytosine-5-)-Methyltransferase 1
  • DNA (Cytosine-5-)-Methyltransferases (metabolism)
  • DNA-Binding Proteins (metabolism)
  • DNA-Cytosine Methylases (metabolism)
  • Dinucleoside Phosphates (metabolism)
  • Gene Expression Regulation, Neoplastic (drug effects, genetics)
  • Gene Silencing (physiology)
  • Liver (enzymology)
  • Liver Neoplasms, Experimental
  • Metallothionein (genetics)
  • Molecular Sequence Data
  • Promoter Regions, Genetic
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction
  • Substrate Specificity

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: